IDEAYA Bioscience partners with Roche on pancreatic cancer treatment combination
IDEAYA Bioscience (IDYA) has partnered with Roche (RHHBY) to evaluate a combination therapy for MTAP-deleted RAS-mutant pancreatic cancer. The collaboration involves IDE892, an MTA-cooperative PRMT5 inhibitor from IDEAYA, and RG6505, a pan-RAS drug from Roche, both currently in Phase 1 trials.
Tickers: $IDYA